Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patient's ...

Trading with an implied upside of 60.5% and an RSI of 34.6, Tempus AI, Inc. (NASDAQ:TEM) has emerged as a notable oversold ...

Men with less common types of prostate cancer have worse cancer control and greater need for radiation therapy after surgery. Oncologic and functional outcomes after robot-assisted radical ...

Prostate cancer stands as a prevalent threat to men's health, ranking second in cancer-related deaths in the United States. Each year, approximately 250,000 men in the U.S. receive a prostate cancer ...

Significant progress in localized prostate cancer has been made, including improved and early detection, targeted biopsy, grading, disease prognostication, and outcome prediction, using imaging and ...

Pathologic concordance between prostate biopsy and radical prostatectomy improves with use of a novel robotic-assisted transperineal fusion biopsy platform. Optimization of risk stratification at ...

Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer The new, tissue-based test service is intended to ...

Microscopic glands of the prostate are segmented (colored) with the new deep-learning pipeline; the image shows a prostate cancer tissue volume, measuring roughly 1 x 1 x 2 mm in size. The prostate ...

The 25-year follow-up of the GÖTEBORG-1 trial 5 assessing active surveillance for screen-detected low and intermediate risk ...